Point72 DIFC Ltd Purchases New Holdings in Seer, Inc. (NASDAQ:SEER)

Point72 DIFC Ltd bought a new stake in shares of Seer, Inc. (NASDAQ:SEER) in the 2nd quarter, Holdings Channel reports. The firm bought 21,100 shares of the company’s stock, valued at approximately $35,000.

Other hedge funds have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in Seer during the 1st quarter valued at $35,000. Quadrature Capital Ltd bought a new stake in shares of Seer during the first quarter worth $56,000. Brandywine Managers LLC bought a new stake in shares of Seer during the fourth quarter worth $86,000. Syon Capital LLC purchased a new stake in shares of Seer during the fourth quarter valued at $94,000. Finally, American Century Companies Inc. grew its holdings in shares of Seer by 42.1% in the second quarter. American Century Companies Inc. now owns 61,752 shares of the company’s stock worth $104,000 after purchasing an additional 18,302 shares during the last quarter. Institutional investors own 75.20% of the company’s stock.

Seer Stock Up 9.5 %

Shares of NASDAQ:SEER opened at $1.96 on Monday. The business’s 50 day moving average is $1.75 and its 200 day moving average is $1.81. The stock has a market cap of $126.63 million, a P/E ratio of -1.50 and a beta of 1.44. Seer, Inc. has a 52-week low of $1.46 and a 52-week high of $2.30.

Seer (NASDAQ:SEER) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. The business had revenue of $3.07 million for the quarter, compared to the consensus estimate of $3.33 million. Seer had a negative return on equity of 21.26% and a negative net margin of 559.21%. During the same quarter in the prior year, the company earned ($0.37) EPS. On average, sell-side analysts anticipate that Seer, Inc. will post -1.27 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley lowered their price objective on shares of Seer from $7.00 to $3.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 13th.

About Seer

Seer, Inc, a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only.